Epigenetics diagnostics involves studying modifications to DNA and associated proteins that regulate gene expression without altering the underlying genetic code. One significant application lies in cancer detection and treatment, where epigenetic alterations are crucial. Epigenetic markers such as DNA methylation patterns or histone modifications are analyzed to identify specific signatures associated with different types of cancer. This information facilitates more accurate cancer diagnosis, prognosis, and personalized treatment strategies tailored to individual patients, ultimately leading to improved outcomes and better disease management.
Global Epigenetics Diagnostic Market size is valued at USD 13,280.13 million in 2023 and is projected to reach USD 57,424.23 million by 2031, with a CAGR of 20.20% during the forecast period of 2024-2031.
To know more, visit https://www.databridgemarketresearch.com/zh/reports/global-epigenetics-diagnostic-market
Below are the Top Epigenetics Diagnostic Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Illumina, Inc.
|
Illumina, a leading player in genomic sequencing technologies, offers solutions for epigenetic research through its sequencing platforms and array-based assays. Its technology enables high-throughput DNA methylation and histone modification analysis, empowering researchers and clinicians in epigenetics diagnostics.
|
|
South America, North America, Asia-Pacific, Europe, and Middle East and Africa
|
In January 2017, Illumina, Inc. launched the NovaSeq Series. This announcement has strengthened the company’s footprint in the market.
|
|
2.
|
Thermo Fisher Scientific Inc.
|
Thermo Fisher provides various tools and services for epigenetics research, including DNA methylation analysis kits, chromatin immunoprecipitation (ChIP) assays, and sequencing platforms. Its comprehensive portfolio supports both basic research and clinical applications in epigenetics diagnostics.
|
|
South America, North America, Asia-Pacific, Europe, and Middle East and Africa
|
Thermo Fisher Scientific Inc. has introduced the Silencer Select Human Epigenetics siRNA Library, a comprehensive tool for researchers studying epigenetic regulation in human diseases. This library contains 1,563 highly potent, chemically modified siRNAs targeting 521 epigenetic enzymes involved in histone acetylation and methylation. Such a robust selection enhances researchers' ability to investigate the role of epigenetic modifications in disease development and progression, potentially leading to advancements in epigenetics diagnostics and therapeutic interventions.
|
|
3.
|
Merck KGaA
|
Merck offers diverse products and services for epigenetics research, including antibodies, reagents, and assay kits for studying DNA methylation, histone modifications, and chromatin remodeling. Its innovative technologies support advancements in epigenetics diagnostics and therapeutic development.
|
|
South America, North America, Asia-Pacific, Europe, and Middle East and Africa
|
In August 2021, Merck KGaA acquired privately held OncoEthix, which is developing a class of epigenetics-based compounds. This acquisition has boosted the company's revenue growth.
|
|
4.
|
Bio-Rad Laboratories, Inc.
|
Bio-Rad offers a variety of products for epigenetics research, including PCR-based assays, chromatin immunoprecipitation kits, and antibodies for studying epigenetic modifications. Its comprehensive solutions cater to the needs of researchers and clinicians in the epigenetics diagnostics market.
|
|
North America, Asia-Pacific, Europe, and others
|
In February 2011, Bio-Rad Laboratories, Inc. launched the EpiQ Chromatin Analysis Kit. This product launch has helped the company increase revenue.
|
|
5.
|
F. Hoffmann-La Roche Ltd.
|
Roche provides innovative tools and technologies for epigenetics research, including sequencing platforms, array-based assays, and reagents for studying DNA methylation and histone modifications. With a focus on precision medicine, Roche's offerings contribute to epigenetics diagnostics and personalized healthcare advancements.
|
|
America, Africa, Asia, Europe, and Oceania
|
In August 2021, F. Hoffmann-La Roche Ltd received FDA approval for the first companion diagnostic to identify dMMR solid tumor patients eligible for anti-PD-1 immunotherapy. Approval provides clinicians access to a fully automated panel of MMR biomarkers tested by immunohistochemistry (IHC), enabling impactful treatment decisions for patients. This helped the company expand its product portfolio and enhance revenue.
|
Conclusion
The global epigenetics diagnostic market is witnessing rapid growth, driven by the increasing recognition of epigenetic alterations in cancer detection and treatment. Companies such as Illumina, Thermo Fisher Scientific, Merck KGaA, Bio-Rad Laboratories, and F. Hoffmann-La Roche are at the forefront, offering innovative solutions for researchers and clinicians. Their contributions are vital in advancing personalized treatment strategies, ultimately improving patient outcomes and revolutionizing disease management in the coming years.
